Skip to main navigation Skip to search Skip to main content

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Lai, Li Hoon (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date21/10/21 → 31/12/24

Keywords

  • Medical oncology
  • IL-2
  • Clinical trial

Clinical Trial Phase

  • Phase I
  • Phase II